Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro and in vivo

Hye Jin Jung, Joong Sup Shim, Hyang Burm Lee, Chang Jin Kim, Takashi Kuwano, Mayumi Ono, Ho Jeong Kwon

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The efficient inhibition of angiogenesis is considered as a promising strategy for the treatment of angiogenesis-related diseases including cancer. Herein, we report that embellistatin, a bicyclic ketone compound known as a microtubule polymerization inhibitor, exhibits anti-angiogenic activity. Embellistatin inhibited in vitro angiogenesis of bovine aortic endothelial cells (BAECs) such as bFGF-induced invasion and tube formation as well as bFGF-induced mouse corneal angiogenesis in vivo. Notably, embellistatin exhibited stronger inhibition activity for the growth of BAECs than that of normal and cancer cell lines. Cell cycle analysis revealed that the compound arrests cell cycle at G2/M phase, which is associated with the increased expression of p21WAF1 and p53 partly. These results demonstrate that embellistatin may serve the basis for the development of new anti-angiogenic agents.

Original languageEnglish
Pages (from-to)376-380
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume353
Issue number2
DOIs
Publication statusPublished - 2007 Feb 9

Fingerprint

Angiogenesis Inhibitors
Microtubules
Polymerization
Endothelial cells
Cells
Endothelial Cells
Corneal Neovascularization
G2 Phase
Cell Cycle Checkpoints
Ketones
Cell Division
Neoplasms
Cell Cycle
Cell Line
In Vitro Techniques
embellistatin
Growth

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Jung, Hye Jin ; Shim, Joong Sup ; Lee, Hyang Burm ; Kim, Chang Jin ; Kuwano, Takashi ; Ono, Mayumi ; Kwon, Ho Jeong. / Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro and in vivo. In: Biochemical and Biophysical Research Communications. 2007 ; Vol. 353, No. 2. pp. 376-380.
@article{924a12fcdb8b44008b43eb6fd412bf24,
title = "Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro and in vivo",
abstract = "The efficient inhibition of angiogenesis is considered as a promising strategy for the treatment of angiogenesis-related diseases including cancer. Herein, we report that embellistatin, a bicyclic ketone compound known as a microtubule polymerization inhibitor, exhibits anti-angiogenic activity. Embellistatin inhibited in vitro angiogenesis of bovine aortic endothelial cells (BAECs) such as bFGF-induced invasion and tube formation as well as bFGF-induced mouse corneal angiogenesis in vivo. Notably, embellistatin exhibited stronger inhibition activity for the growth of BAECs than that of normal and cancer cell lines. Cell cycle analysis revealed that the compound arrests cell cycle at G2/M phase, which is associated with the increased expression of p21WAF1 and p53 partly. These results demonstrate that embellistatin may serve the basis for the development of new anti-angiogenic agents.",
author = "Jung, {Hye Jin} and Shim, {Joong Sup} and Lee, {Hyang Burm} and Kim, {Chang Jin} and Takashi Kuwano and Mayumi Ono and Kwon, {Ho Jeong}",
year = "2007",
month = "2",
day = "9",
doi = "10.1016/j.bbrc.2006.12.026",
language = "English",
volume = "353",
pages = "376--380",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "2",

}

Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro and in vivo. / Jung, Hye Jin; Shim, Joong Sup; Lee, Hyang Burm; Kim, Chang Jin; Kuwano, Takashi; Ono, Mayumi; Kwon, Ho Jeong.

In: Biochemical and Biophysical Research Communications, Vol. 353, No. 2, 09.02.2007, p. 376-380.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro and in vivo

AU - Jung, Hye Jin

AU - Shim, Joong Sup

AU - Lee, Hyang Burm

AU - Kim, Chang Jin

AU - Kuwano, Takashi

AU - Ono, Mayumi

AU - Kwon, Ho Jeong

PY - 2007/2/9

Y1 - 2007/2/9

N2 - The efficient inhibition of angiogenesis is considered as a promising strategy for the treatment of angiogenesis-related diseases including cancer. Herein, we report that embellistatin, a bicyclic ketone compound known as a microtubule polymerization inhibitor, exhibits anti-angiogenic activity. Embellistatin inhibited in vitro angiogenesis of bovine aortic endothelial cells (BAECs) such as bFGF-induced invasion and tube formation as well as bFGF-induced mouse corneal angiogenesis in vivo. Notably, embellistatin exhibited stronger inhibition activity for the growth of BAECs than that of normal and cancer cell lines. Cell cycle analysis revealed that the compound arrests cell cycle at G2/M phase, which is associated with the increased expression of p21WAF1 and p53 partly. These results demonstrate that embellistatin may serve the basis for the development of new anti-angiogenic agents.

AB - The efficient inhibition of angiogenesis is considered as a promising strategy for the treatment of angiogenesis-related diseases including cancer. Herein, we report that embellistatin, a bicyclic ketone compound known as a microtubule polymerization inhibitor, exhibits anti-angiogenic activity. Embellistatin inhibited in vitro angiogenesis of bovine aortic endothelial cells (BAECs) such as bFGF-induced invasion and tube formation as well as bFGF-induced mouse corneal angiogenesis in vivo. Notably, embellistatin exhibited stronger inhibition activity for the growth of BAECs than that of normal and cancer cell lines. Cell cycle analysis revealed that the compound arrests cell cycle at G2/M phase, which is associated with the increased expression of p21WAF1 and p53 partly. These results demonstrate that embellistatin may serve the basis for the development of new anti-angiogenic agents.

UR - http://www.scopus.com/inward/record.url?scp=33845880644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845880644&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2006.12.026

DO - 10.1016/j.bbrc.2006.12.026

M3 - Article

C2 - 17184734

AN - SCOPUS:33845880644

VL - 353

SP - 376

EP - 380

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 2

ER -